

Mericitabine

Catalog No: tcsc0596



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

940908-79-2

Formula:

$C_{18}H_{26}FN_3O_6$

Pathway:

Metabolic Enzyme/Protease;Anti-infection

Target:

HCV Protease;HCV

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

RG 7128;R-7128;PSI 6130 diisobutyrate

Observed Molecular Weight:


399.41

Product Description

Mericitabine (R-7128) is a nucleoside inhibitor of the **HCV NS5B polymerase** that acts as an RNA chain terminator and prevents elongation of RNA transcripts during replication.

IC50 & Target: HCV NS5B polymerase^[1]

In Vitro: Mericitabine (R-7128) is an oral prodrug of PSI-6130, a cytidine analogue. Pre-clinical observations demonstrated that PSI-6130 has an EC₉₀ value of 4.6±2 μM in the HCV replicon assay. Mericitabine shows high specificity for HCV, minimal cytotoxicity and does not affect mitochondrial DNA. PSI-6130 is converted through phosphorylation by cellular kinases to an active 5'-triphosphate metabolite, which inhibits the NS5B RNA polymerase of HCV. Mericitabine demonstrates a relatively good safety profile and significant potency against HCV-1^[2]. Mericitabine is a first-in class nucleoside polymerase inhibitor (NPI), which requires intracellular uptake and phosphorylation to two active triphosphates. R-7128 is an oral cytidine nucleoside analog prodrug that exhibits strong antiviral effectiveness against the HCV polymerase across all HCV genotypes^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!